Advertisement

BioDrugs

, Volume 28, Issue 3, pp 297–312 | Cite as

Attenuation of Carbon Tetrachloride-Induced Hepatic Injury with Curcumin-Loaded Solid Lipid Nanoparticles

  • Neha Singh
  • Neeraj Khullar
  • Vandita Kakkar
  • Indu Pal Kaur
Original Research Article

Abstract

Background and Objectives

Curcumin, an established pleiotropic agent, has potential for hepatoprotection owing to its powerful antioxidant, anti-inflammatory, and antifibrogenic properties. However, its poor bioavailability limits its use in therapeutics. In this study, we aimed to package curcumin into solid lipid nanoparticles (C-SLNs) to improve its bioavailability and compare the efficacy of C-SLNs with that of free curcumin and silymarin, a well-established hepatoprotectant in clinical use, against carbon tetrachloride (CCl4)-induced hepatic injury in rats, post-induction. A self-recovery group to which no treatment was given was also employed for quantifying self-healing of hepatic tissue, if any.

Material and Methods

C-SLNs (particle size 147.6 nm), prepared using a microemulsification technique, were administered to rats post-treatment with CCl4 (1 ml/kg body weight [BW] twice weekly for 2 weeks, followed by 1.5 ml/kg BW twice weekly for the subsequent 2 weeks). The extent of liver damage and repair in terms of histopathology and levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), oxidative stress markers (malondialdehyde, superoxide dismutase, and reduced glutathione) and a pro-inflammatory response marker, tumor necrosis factor (TNF)-α, were determined in both the CCl4 group and the treatment groups.

Results

C-SLNs (12.5 mg/kg) significantly (p < 0.001–0.005) attenuated histopathological changes and oxidative stress, and also decreased induction of ALT, AST, and TNF-α in comparison with free curcumin (100 mg/kg), silymarin (25 mg/kg), and self-recovery groups.

Conclusion

Curcumin could be used as a therapeutic agent for hepatic disorders, provided it is loaded into a suitable delivery system.

Keywords

Curcumin CCl4 Hepatic Injury Silymarin Solid Lipid Nanoparticles 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The Senior Research Fellowship and contingent grant provided to Neha Singh by the Indian Council of Medical Research (ICMR), New Delhi, India, is gratefully acknowledged. The authors are thankful to Mr. Dinesh Sharma and the Sophisticated Analytical Instrumentation Facility (SAIF), Panjab University, Chandigarh, India, for transmission electron microscopic analysis. The authors declare that they have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Jayaprakasha G, Rao L, Sakariah K. Antioxidant activities of curcumin, demethoxycurcumin and bisdemethoxycurcumin. Food Chem. 2006;98(4):720–4.CrossRefGoogle Scholar
  2. 2.
    Tonnesen HH, Greenhil JVL. Studies on curcumin and curcuminoids XXII. Curcumin as a reducing agent and as a radical scavanger. Int J Pharm. 1992;87:79–87.CrossRefGoogle Scholar
  3. 3.
    Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress. Biochim Biophys Acta. 2007;1770(6):989–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Arora RB, Kapoor V, Basu N, Jain AP. Anti-inflammatory studies on Curcuma longa (turmeric). Indian J Med Res. 1971;59(8):1289–95.PubMedGoogle Scholar
  5. 5.
    Subramanian L, Selvam R, Mudaliar AL. Prevention of CCl4-induced hepatotoxicity by aqueous extract of tumeric. Nutr Res. 1999;19:429–41.CrossRefGoogle Scholar
  6. 6.
    Tonnesen HH, Masson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm. 2002;244(1–2):127–35.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15(12):1867–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Ammon HPT, Wahl MA. Pharmacology of Curcuma longa. Planta Medica. 1991;57:1–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7(7):1894–900.PubMedGoogle Scholar
  10. 10.
    Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330(1–2):155–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology. 1980;16(3):259–65.PubMedCrossRefGoogle Scholar
  12. 12.
    Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005;104(6):1322–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Ma Z, Shayeganpour A, Brocks DR, Lavasanifar A, Samuel J. High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr. 2007;21(5):546–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal. 2006;40(3):720–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.PubMedCrossRefGoogle Scholar
  17. 17.
    Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, Maekawa T, Venugopal K, Kumar DS. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS ONE. 2012;7(3):e32616. doi: 10.1371/journal.pone.0032616.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Yadav A, Lomash V, Samim M, Flora SJ. Curcumin encapsulated in chitosan nanoparticles: a novel strategy for the treatment of arsenic toxicity. Chem Biol Interact. 2012;199(1):49–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Grama CN, Suryanarayana P, Patil MA, Raghu G, Balakrishna N, et al. Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. PLoS ONE. 2013;8(10):e78217. doi: 10.1371/journal.pone.0078217.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Yallapu MM, Othman SF, Curtis ET, Bauer NA, Chauhan N, Kumar D, Jaggi M, Chauhan SC. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomed. 2012;7:1761–79.Google Scholar
  21. 21.
    Yallapu MM, Ebeling MC, Khan S, Sundram V, Chauhan N, Gupta BK, Puumala SE, Jaggi M, Chauhan SC. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther. 2013;12(8):1471–80. doi: 10.1158/1535-7163.PubMedCrossRefGoogle Scholar
  22. 22.
    Sandhir R, Yadav A, Mehrotra A, Sunkaria A, Singh A, Sharma S. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s disease. Neuro Mol Med. 2013. doi: 10.1007/s12017-013-8261-y.
  23. 23.
    Bisht S, Khan MA, Bekhit M, Bai H, Cornish T, Mizuma M, Rudek MA, Zhao M, Maitra A, Ray B, Lahiri D, Maitra A, Anders RA. A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Lab Invest. 2011;91(9):1383–95.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Sankar P, Gopal Telang A, Kalaivanan R, Karunakaran V, Manikam K, Sarkar SN. Effects of nanoparticle-encapsulated curcumin on arsenic-induced liver toxicity in rats. Environ Toxicol. 2013. doi: 10.1002/tox.21940.
  25. 25.
    Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles for brain targeting. J Control Release. 2008;127:97–109.PubMedCrossRefGoogle Scholar
  26. 26.
    Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res. 2011;55(3):495–503.PubMedCrossRefGoogle Scholar
  27. 27.
    Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs—a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113(1–3):151–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mader K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release. 2004;95(2):217–27.PubMedCrossRefGoogle Scholar
  29. 29.
    Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004;56(12):1527–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2010;11(2):582–7.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Freitas C, Muller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN (TM)) dispersions. Int J Pharm. 1998;168:221–9.CrossRefGoogle Scholar
  32. 32.
    Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver Int. 2009;29(10):1457–66.PubMedCrossRefGoogle Scholar
  33. 33.
    Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases. J Appl Toxicol. 2008;28(2):93–103.PubMedCrossRefGoogle Scholar
  34. 34.
    Rechnagel RO, Glende EA Jr. Carbon tetrachloride hepatotoxicity: an example of lethal cleavage. CRC Crit Rev Toxicol. 1973;2(3):263–97.PubMedCrossRefGoogle Scholar
  35. 35.
    Perez Tamayo R. Is cirrhosis of the liver experimentally produced by CCl4 and adequate model of human cirrhosis? Hepatology. 1983;3(1):112–20.PubMedCrossRefGoogle Scholar
  36. 36.
    Du WD, Zhang YE, Zhai WR, Zhou XM. Dynamic changes of type I, III and IV collagen synthesis and distribution of collagen-producing cells in carbon tetrachloride-induced rat liver fibrosis. World J Gastroenterol. 1999;5(5):397–403.PubMedGoogle Scholar
  37. 37.
    Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006;124(5):491–504.PubMedGoogle Scholar
  38. 38.
    Kakkar V, Kaur IP. Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol. 2011;49(11):2906–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC–MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853(1–2):183–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh). 1978;43(2):86–92.CrossRefGoogle Scholar
  41. 41.
    Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol. 2005;27(2):127–44.PubMedCrossRefGoogle Scholar
  42. 42.
    Gopal N, Sengottuvelu S. Hepatoprotective activity of Clerodendrum inerme against CCl4 induced hepatic injury in rats. Fitoterapia. 2008;79(1):24–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28(1):56–63.PubMedGoogle Scholar
  44. 44.
    Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem J. 1966;99(3):667–76.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys. 1978;186(1):189–95.PubMedCrossRefGoogle Scholar
  46. 46.
    Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology. 1974;11(3):151–69.PubMedCrossRefGoogle Scholar
  47. 47.
    Morisco F, Vitaglione P, Amoruso D, Russo B, Fogliano V, Caporaso N. Foods and liver health. Mol Aspects Med. 2008;29(1–2):144–50.PubMedCrossRefGoogle Scholar
  48. 48.
    Slater TF. Free-radical mechanisms in tissue injury. Biochem J. 1984;222(1):1–15.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Liu SL, Degli Esposti S, Yao T, Diehl AM, Zern MA. Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology. 1995;22(5):1474–81.PubMedGoogle Scholar
  50. 50.
    Hernandez-Munoz R, Diaz-Munoz M, Chagoya de Sanchez V. Possible role of cell redox state on collagen metabolism in carbon tetrachloride-induced cirrhosis as evidenced by adenosine administration to rats. Biochim Biophys Acta. 1994;1200(2):93–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003;33(2):105–36.PubMedCrossRefGoogle Scholar
  52. 52.
    Czaja MJ, Xu J, Alt E. Prevention of carbon tetrachloride-induced rat liver injury by soluble tumor necrosis factor receptor. Gastroenterology. 1995;108(6):1849–54.PubMedCrossRefGoogle Scholar
  53. 53.
    Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol. 2008;73(2):399–409.PubMedCrossRefGoogle Scholar
  54. 54.
    He SM, Chan E, Zhou SF. ADME properties of herbal medicines in humans: evidence, challenges and strategies. Curr Pharm Des. 2011;17(4):357–407.PubMedCrossRefGoogle Scholar
  55. 55.
    Bhandari R, Kaur IP. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm. 2013;441:202–12.PubMedCrossRefGoogle Scholar
  56. 56.
    Bhandari R, Kaur IP. A method to prepare solid lipid nanoparticles with improved entrapment efficiency of hydrophilic drugs. Curr Nanosci. 2013;9:211–20.CrossRefGoogle Scholar
  57. 57.
    Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release. 2007;118(1):7–17.PubMedCrossRefGoogle Scholar
  58. 58.
    Liang HF, Yang TF, Huang CT, Chen MC, Sung HW. Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. J Control Release. 2005;105(3):213–25.PubMedCrossRefGoogle Scholar
  59. 59.
    Hashida M, Takemura S, Nishikawa M, Takakura Y. Targeted delivery of plasmid DNA complexed with galactosylated poly(l-lysine). J Control Release. 1998;53(1–3):301–10.PubMedCrossRefGoogle Scholar
  60. 60.
    Li L, Wang H, Ong ZY, Xu K, Ee PLR, Zheng S, Hedrick JL, Yang YY. Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today. 2010;5:296–312.CrossRefGoogle Scholar
  61. 61.
    He J, Hou S, Lu W, Zhu L, Feng J. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J Biomed Nanotechnol. 2007;3(4):195–202.CrossRefGoogle Scholar
  62. 62.
    Kakkar V, Kaur IP. Antidepressant activity of curcumin loaded solid lipid nanoparticles (C-SLNs) in mice. Am J Pharm Tech Res. 2012;2(3):34–46.Google Scholar
  63. 63.
    Kakkar V, Muppu SK, Chopra K, Kaur IP. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm. 2013;6411(13):00059.Google Scholar
  64. 64.
    Kakkar V, Mishra AK, Chuttani K, Kaur IP. Proof of concept studies to confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain. Int J Pharm. 2013;448(2):354–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Dong MX, Jia Y, Zhang YB, Li CC, Geng YT, Zhou L, et al. Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation. World J Gastroenterol. 2009;15(38):4753–62.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Sallie R, Tredger JM, Williams R. Drugs and the liver. Part 1: Testing liver function. Biopharm Drug Dispos. 1991;12(4):251–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Javed S, Kohli K, Ali M. Reassessing bioavailability of silymarin. Altern Med Rev. 2011;16(3):239–49.PubMedGoogle Scholar
  68. 68.
    Mansour MA. Protective effects of thymoquinone and desferrioxamine against hepatotoxicity of carbon tetrachloride in mice. Life Sci. 2000;66(26):2583–91.PubMedCrossRefGoogle Scholar
  69. 69.
    Barry J, Fritz M, Brender JR, Smith PE, Lee DK, Ramamoorthy A. Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. J Am Chem Soc. 2009;131(12):4490–8.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Curtis SJ, Moritz M, Snodgrass PJ. Serum enzymes derived from liver cell fractions. I. The response to carbon tetrachloride intoxication in rats. Gastroenterology. 1972;62(1):84–92.PubMedGoogle Scholar
  71. 71.
    Feher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol. 2012;13(1):210–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489–92.PubMedGoogle Scholar
  73. 73.
    Blair IA. Endogenous glutathione adducts. Curr Drug Metab. 2006;7(8):853–72.PubMedCrossRefGoogle Scholar
  74. 74.
    Shukitt-Hale B, Erat SA, Joseph JA. Spatial learning and memory deficits induced by dopamine administration with decreased glutathione. Free Radic Biol Med. 1998;24(7–8):1149–58.PubMedCrossRefGoogle Scholar
  75. 75.
    Roy S, Sannigrahi S, Majumdar S, Ghosh B, Sarkar B. Resveratrol regulates antioxidant status, inhibits cytokine expression and restricts apoptosis in carbon tetrachloride induced rat hepatic injury. Oxid Med Cell Longev. 2011;2011(703676):15.Google Scholar
  76. 76.
    Hernandez-Munoz I, de la Torre P, Sanchez-Alcazar JA, Garcia I, Santiago E, Munoz-Yague MT, et al. Tumor necrosis factor alpha inhibits collagen alpha 1(I) gene expression in rat hepatic stellate cells through a G protein. Gastroenterology. 1997;113(2):625–40.PubMedCrossRefGoogle Scholar
  77. 77.
    Berghe TV, Denecker G, Brouckaert G, Vadimovisch Krysko D, D’Herde K, Vandenabeele P. More than one way to die: methods to determine TNF-induced apoptosis and necrosis. Methods Mol Med. 2004;98:101–26.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Neha Singh
    • 1
  • Neeraj Khullar
    • 1
  • Vandita Kakkar
    • 2
  • Indu Pal Kaur
    • 2
  1. 1.Department of BiotechnologyPanjab UniversityChandigarhIndia
  2. 2.Department of PharmaceuticsUniversity Institute of Pharmaceutical Sciences, Panjab UniversityChandigarhIndia

Personalised recommendations